Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
More women are seeking testosterone therapy for menopause symptoms, and prescription rates have nearly tripled since 2020. But with no FDA-approved product for women, patients are hitting walls at major pharmacies like Amazon, CVS, and Walgreens. The FDA is now stepping in to review the evidence — and the debate over what testosterone can actually do for women is heating up.
Women turning to testosterone therapy for menopause-related symptoms are finding themselves caught in a frustrating gap: prescriptions are rising fast, but pharmacies are increasingly rejecting or delaying them. Since there's no FDA-approved testosterone product for women, patients must use doses designed for men — often splitting or discarding portions — which has prompted some major pharmacies to cite safety and compliance concerns as grounds for refusal.
The off-label use is backed by medical guidelines only for hypoactive sexual desire disorder (HSDD) in menopausal women. Yet clinicians are increasingly prescribing it for fatigue, muscle loss, and mood — uses that lack robust clinical evidence. Experts like Dr. Stephanie Faubion of the Mayo Clinic caution that social media hype has outpaced the science.
By the Numbers:
Why it matters: The FDA is holding a public workshop to review the evidence for testosterone use in menopausal women — a signal that regulatory clarity may be on the horizon. For clinicians, clearer guidance and an approved women-specific product could reduce prescription barriers and help patients access a therapy that, for the right indication, has real clinical support.
